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a  b  s  t  r  a  c  t
Abacavir-induced liver toxicity is a rare event almost exclusively occurring in HLA B*5701-
positive patients. Herein, we report one case of abnormal liver function tests occurring in
a  young HLA B*5701-negative woman on a stable nevirapine-based regimen with no his-
tory of liver problems or alcohol abuse after switching to abacavir from tenofovir. We  also
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emtricitabine/NVP to ABC/lamivudine/NVP after sevenIntroduction
Drug-induced hepatotoxicity represents an important side
effect of highly active antiretroviral therapy (HAART), com-
plicates the management of HIV-infected patients and,
although infrequently, may have serious consequences.1 Pos-
sible pathogenic mechanisms involved in hepatotoxicity are
multiple, including direct drug toxicity, immune reconstitu-
tion in the presence of hepatitis C (HCV) and/or hepatitis
B (HBV) co-infections, hypersensitivity reactions with liver
involvement, and mitochondrial toxicity.1
Abacavir (ABC)-induced liver toxicity is a rare event almost
exclusively occurring in HLA B*5701-positive patients,2 with
a handful of cases reported in non carriers of the HLA allele
3,4risk. All cases happened in patients on a stable nevirap-
ine (NVP)-based regimen after switching to ABC from another
nucleoside analog. Herein, we  report one case of abnormal
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woman on a stable NVP-based regimen with no history of liver
problems or alcohol abuse after switching to ABC. In order
to assess the incidence of ABC liver toxicity in the HIV  pop-
ulation treated with ABC, lamivudine, and NVP, which is a
poorly investigated but currently used combination in clinical
practice, mainly in countries with economic constraints, we
investigated the reasons for ABC discontinuation in patients
on NVP-based regimens from our clinical database.
Case  report
A 33-year-old woman was switched from tenofovir/years on initial treatment to avoid tenofovir related long-term
toxicity. Our choice was based on the low body weight of the
patient – which is risk factor for the development of long-term
e under the CC BY-NC-ND license (http://creativecommons.org/
Users December 27, 2016.
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enofovir complications5 – and the observed mild increase
n serum creatinine concentrations. She tested negative for
LA B*5701 and hepatitis viruses. Her transaminases levels
ad always been normal along her antiretroviral treatment
ut eight weeks after switching to ABC aspartate amino-
ransferase (AST) and alanine aminotransferase (ALT) levels
rogressively increased to 222 and 518 UI/mL, respectively. The
atient has always been asymptomatic. Serology for hepatitis
 (HAV IgM), hepatitis B (HBsAg, HBcAbIgM), and hepatitis
 (HCVAb) were negative, as were hepatitis C viral load
HCV RNA undetectable). Autoantibody screening tests were
egative. The patient did not take concomitant medications
fter switching to ABC and was not given acetaminophen, a
rug known to induce liver toxicity eventually exacerbated
y ABC.6 Given the previous long term tolerability to NVP,
BC was discontinued and the patient was switched back
o tenofovir with subsequent normalization of AST and ALT
ithin six weeks.
In order to properly address the incidence of ABC liver
oxicity in patients on stable treatment with NVP, we retro-
pectively searched our clinical database and identiﬁed 1004
ale and female HIV-infected patients referring to our Depart-
ent between 2000 and 2013 who began receiving ABC as part
f their ﬁrst or subsequent antiretroviral treatment regimen.
ighty-three HIV-infected patients (51 males, 32 females), with
 median age of 46 years (range 30–72), received a stable NVP-
ontaining regimen before starting ABC. The main reasons for
witching to ABC were (a) lipodystrophy and lipid abnormal-
ties in patients treated with zidovudine (27 patients); (b) to
void tenofovir related toxicity (38 patients); stavudine and
idanosine replacement (10 patients). Overall, 26 out of the
3 (24%) patients subsequently discontinued ABC treatment
ue to the following reasons: virologic failure (n = 11), rash
n = 5), in three cases before the availability of genetic testing
or HLA B*5701, gastrointestinal side effects (n = 2), pregnancy
n = 2), patient request (n = 2), one patient discontinued due to
hange in treatment strategy, one patient due to high car-
iovascular risk, and hepatotoxicity (n = 2, both cases tested
egative for HLA B*5701). Of the two suspensions due to hepa-
otoxicity, one patient had no viral hepatitis co-infection and
resented clinical and demographic characteristics similar to
hose described in previous reports,3,4 while the other was
oinfected with HCV and had not had previous raise in liver
nzymes. Interestingly, 82% (9 out of the 11 pts) of the virologic
ailures were observed in patients with a long history of HIV
reatment including antiretroviral regimens that are no longer
ecommended.
iscussion
BC-induced liver injury in the context of a negative HLA
*5701 test is an uncommon event. As a matter of fact,
xtensive evidence is now available showing that HLA-B*5701
creening is an effective way to prevent hypersensitivity to
BC in susceptible subjects.7,8 To the best of our knowl-
dge only three cases of hepatotoxicity occurring in HLA
*5701-negative patients with no viral hepatitis co-infection
r history of alcohol abuse have been reported; all cases were
n a stable NVP-based regimen after switching to ABC from
Downloaded from ClinicalKey.jp at ClinicalKey Japan Guest U
For personal use only. No other uses without permission. Copyright ©2016;2 0(5):502–504 503
another nucleoside analog.3,4 Here, we  conﬁrm these ﬁndings
by documenting that in our cohort ABC-related hepatotoxicity
was an uncommon, but clinically relevant event. A phar-
macokinetic drug-to-drug interaction between ABC and NVP
is unlikely because ABC is not metabolized by cytochromial
enzymes.9 We  have also excluded a potential contribution
of acetaminophen on the observed ABC/NVP-related liver
toxicity6 because this drug was used, if any, in very few
patients from our cohorts and for short time periods. Accord-
ingly, potential pharmacodynamic mechanisms explaining
ABC/NVP liver toxicity can be eventually advocated. Indeed,
evidence is available showing that both drugs separately can
favor the bioactivation of reactive molecules capable of form-
ing protein products ultimately leading to liver toxicity.10–12
On the other hand, it should be considered that very limited
and scanty data are available not only on the safety but also
on the efﬁcacy ABC/lamivudine/NVP combination,13,14 despite
the fact that this regimen has now become a very attractive
option for the very low cost, limited metabolic impact, and
low pill burden. We, therefore, extended previous ﬁndings by
assessing the frequency of ABC-related hepatotoxicity in HIV-
infected patients on NVP based-regimens and by describing
the efﬁcacy of this regimen in a real life scenario. Indeed, a
higher incidence of virologic failure was found in our cohort
of patients compared with the only available study to date
which has formally investigated ABC/lamivudine/NVP as a
simpliﬁcation strategy for HIV patients with undetectable viral
load.13 The possibility that the increased pill burden (as in
the case of switching from zidovudine + lamivudine coformu-
lation to ABC/lamivudine as single components) might have
contributed, at least in part, to the virologic failures observed
in patients cannot be deﬁnitively ruled out. It should be con-
sidered, however, that large part of our failures were driven
by events occurring in patients with long term history of
antiretroviral therapy which included mono or dual regimens
no longer recommended. As a result, it can be reasonably spec-
ulated that some of the virologic failures apparently observed
with ABC may have been signiﬁcantly inﬂuenced by previous
antiretroviral regimens.
In conclusion, clinicians should remain alert for signs of
hepatitis in patients treated with ABC, while, at the same time,
consider the efﬁcacy of ABC/lamivudine/NVP combination as
a simpliﬁcation option only in patients not previously treated
with suboptimal antiretroviral regimens.
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